Acro Biomedical (ACBM) Free Cash Flow (2016 - 2025)
Acro Biomedical (ACBM) has 10 years of Free Cash Flow data on record, last reported at -$25377.0 in Q4 2025.
- For Q4 2025, Free Cash Flow fell 141.34% year-over-year to -$25377.0; the TTM value through Dec 2025 reached -$196302.0, down 435.0%, while the annual FY2025 figure was -$196302.0, 435.0% down from the prior year.
- Free Cash Flow reached -$25377.0 in Q4 2025 per ACBM's latest filing, up from -$54410.0 in the prior quarter.
- Across five years, Free Cash Flow topped out at $432770.0 in Q2 2021 and bottomed at -$345777.0 in Q2 2022.
- Average Free Cash Flow over 5 years is -$4829.3, with a median of -$11590.5 recorded in 2022.
- Peak YoY movement for Free Cash Flow: skyrocketed 3228.07% in 2022, then crashed 1411.59% in 2024.
- A 5-year view of Free Cash Flow shows it stood at -$60506.0 in 2021, then skyrocketed by 82.53% to -$10568.0 in 2022, then dropped by 19.35% to -$12613.0 in 2023, then grew by 16.63% to -$10515.0 in 2024, then crashed by 141.34% to -$25377.0 in 2025.
- Per Business Quant database, its latest 3 readings for Free Cash Flow were -$25377.0 in Q4 2025, -$54410.0 in Q3 2025, and -$93984.0 in Q2 2025.